Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

Eikon Therapeutics / Equity Capital Markets

<ul>
<li>Eikon Therapeutics has filed for an initial public offering, seeking to list its common stock on the Nasdaq Global Market under the ticker EIKN .</li>
<li>The company is offering 17.65 million shares at an expected price range of $16.00 to $18.00 , implying gross proceeds of approximately $300 million at the $17.00 midpoint , before underwriter fees.</li>
<li>At the midpoint, Eikon would debut with an implied post-IPO market capitalization of roughly $860 million , excluding any exercise of the underwriters’ option to purchase additional shares.</li>
</ul>


Eikon Therapeutics has filed for an initial public offering, seeking to list its common stock on the Nasdaq Global Market under the ticker EIKN .
The company is offering 17.65 million shares at an expected price range of $16.00 to $18.00 , implying gross proceeds of approximately $300 million at the $17.00 midpoint , before underwriter fees.
At the midpoint, Eikon would debut with an implied post-IPO market capitalization of roughly $860 million , excluding any exercise of the underwriters’ option to purchase additional shares.


Eikon Therapeutics Files for IPO as Platform-Driven Oncology Innovation Moves Toward Late-Stage Validation

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>Eikon Therapeutics (EIKN) set IPO terms for 17.6 million shares at $16–$18, targeting a market capitalization of up to $908 million valuation </li>
<li>Lead candidate EIK1001 is in a global Phase 2/3 registrational trial for advanced melanoma, with additional lung cancer and oncology programs underway.</li>
<li>The IPO values Eikon below its 2025 Series D valuation above $1.5 billion, offering a discounted entry amid improving late-stage biotech sentiment.</li>
</ul>


Eikon Therapeutics (EIKN) set IPO terms for 17.6 million shares at $16–$18, targeting a market capitalization of up to $908 million valuation 
Lead candidate EIK1001 is in a global Phase 2/3 registrational trial for advanced melanoma, with additional lung cancer and oncology programs underway.
The IPO values Eikon below its 2025 Series D valuation above $1.5 billion, offering a discounted entry amid improving late-stage biotech sentiment.


Eikon Therapeutics (EIKN): Biotech Targeting Advanced Melanoma Sets Terms

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Oncology-Focused pre-clinical stage biopharmaceutical company, Eikon Therapeutics has filed for a proposed IPO for listing of newly issued common stock on the Nasdaq under the symbol "EIKN".</li>
<li>The company mainly intends to use the IPO proceeds to advance the clinical development of four of its pipeline assets and fund the preclinical and potential clinical development of EIK1006.</li>
<li>Eikon is entering a catalyst heavy 2026, with multiple trial readout expected during the second half of the year. Positive trial result will push them one step forward to approval.</li>
</ul>


Oncology-Focused pre-clinical stage biopharmaceutical company, Eikon Therapeutics has filed for a proposed IPO for listing of newly issued common stock on the Nasdaq under the symbol "EIKN".
The company mainly intends to use the IPO proceeds to advance the clinical development of four of its pipeline assets and fund the preclinical and potential clinical development of EIK1006.
Eikon is entering a catalyst heavy 2026, with multiple trial readout expected during the second half of the year. Positive trial result will push them one step forward to approval.


Eikon Therapeutics Pre-IPO: 2026 Will Be a Catalyst Heavy Year for Late-Stage Oncology Candidates

<ul>
<li>Eikon Therapeutics (EIKN US) filed for its IPO on January 9, targeting a late-January or early-February market debut.</li>
<li>Lead candidate EIK1001, a TLR7/8 dual-agonist, is in global Phase 2/3 trials with pembrolizumab for advanced melanoma and Phase 2 NSCLC studies.</li>
<li>Eikon has raised over $1.1 billion across multiple rounds and collaborates with Seven and Eight Biotherapeutics and Cleave Therapeutics to expand its oncology pipeline.</li>
</ul>


Eikon Therapeutics (EIKN US) filed for its IPO on January 9, targeting a late-January or early-February market debut.
Lead candidate EIK1001, a TLR7/8 dual-agonist, is in global Phase 2/3 trials with pembrolizumab for advanced melanoma and Phase 2 NSCLC studies.
Eikon has raised over $1.1 billion across multiple rounds and collaborates with Seven and Eight Biotherapeutics and Cleave Therapeutics to expand its oncology pipeline.


Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma

IMPACT Therapeutics / Equity Capital Markets

<ul>
<li>Impact Therapeutics, a commercial-stage biotechnology company, has launched its HK IPO consisting of 42M H shares. The offer price is HK$21.75/share and shares will be sold in multiples of 200.</li>
<li>The company intends to raise $117M mainly to fund its R&amp;D.  The subscription period will close on May 8, with the shares expected to make trading debut on May 13.</li>
<li>The company’s self-developed core product, senaparib has been commercialized in China in January 2025 as a first-line maintenance therapy for ovarian cancer across all patient populations regardless of mutation status.</li>
</ul>


Impact Therapeutics, a commercial-stage biotechnology company, has launched its HK IPO consisting of 42M H shares. The offer price is HK$21.75/share and shares will be sold in multiples of 200.
The company intends to raise $117M mainly to fund its R&amp;D.  The subscription period will close on May 8, with the shares expected to make trading debut on May 13.
The company’s self-developed core product, senaparib has been commercialized in China in January 2025 as a first-line maintenance therapy for ovarian cancer across all patient populations regardless of mutation status.


Impact Therapeutics IPO: Clinically Compelling Core Product Lays Solid Foundation for Growth

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eikon Therapeutics (EIKN US)

Eikon Therapeutics Files for IPO as Platform-Driven Oncology Innovation Moves Toward Late-Stage Validation

Eikon Therapeutics has filed for an initial public offering, seeking to list its common stock on the Nasdaq Global Market under the ticker EIKN...

IPO Prophet

Eikon Therapeutics (EIKN): Biotech Targeting Advanced Melanoma Sets Terms

Eikon Therapeutics sets IPO terms for $16-$18 per share, targeting up to $908 million valuation. Lead candidate EIK1001 in Phase 2/3 trial for...

IPO Boutique

Eikon Therapeutics Pre-IPO: 2026 Will Be a Catalyst Heavy Year for Late-Stage Oncology Candidates

Late-stage biopharmaceutical company, Eikon Therapeutics is considering Nasdaq listing under the symbol "EIKN" to advance its four clinical-stage...

Tina Banerjee

Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma

Eikon Therapeutics files for IPO, targeting market debut in late-January or early-February with lead candidate in global Phase 2/3 trials for...

IPO Boutique

Impact Therapeutics IPO: Clinically Compelling Core Product Lays Solid Foundation for Growth

Impact Therapeutics seeks to raise $117M via HK IPO consisting of 42M H shares at the offer price of HK$21.75/share mainly to fund its R&D. The...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Eikon Therapeutics Files for IPO as Platform-Driven Oncology Innovation Moves Toward Late-Stage Validation

Eikon Therapeutics has filed for an initial public offering, seeking to list its common stock on the Nasdaq Global Market under the ticker EIKN...

IPO Prophet

Eikon Therapeutics (EIKN): Biotech Targeting Advanced Melanoma Sets Terms

​Eikon Therapeutics sets IPO terms for $16-$18 per share, targeting up to $908 million valuation. Lead candidate EIK1001 in Phase 2/3 trial for...

IPO Boutique

Eikon Therapeutics Pre-IPO: 2026 Will Be a Catalyst Heavy Year for Late-Stage Oncology Candidates

Late-stage biopharmaceutical company, Eikon Therapeutics is considering Nasdaq listing under the symbol "EIKN" to advance its four clinical-stage...

Tina Banerjee

Eikon Therapeutics (EIKN): Peeking at the IPO Prospectus of Targeting Advanced Melanoma

​Eikon Therapeutics files for IPO, targeting market debut in late-January or early-February with lead candidate in global Phase 2/3 trials for...

IPO Boutique

Impact Therapeutics IPO: Clinically Compelling Core Product Lays Solid Foundation for Growth

Impact Therapeutics seeks to raise $117M via HK IPO consisting of 42M H shares at the offer price of HK$21.75/share mainly to fund its R&D. The...

Tina Banerjee

Eikon Therapeutics sets IPO terms for $16-$18 per share, targeting up to $908 million valuation. Lead candidate EIK1001 in Phase 2/3 trial for...

Eikon Therapeutics files for IPO, targeting market debut in late-January or early-February with lead candidate in global Phase 2/3 trials for...